Andre Baruchel
Overview
Explore the profile of Andre Baruchel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
282
Citations
9015
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvo C, Mornet C, Storey C, Halfon-Domenech C, Pochon C, Tabone M, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40033132
No abstract available.
2.
Courtois L, Pinton A, Cabannes-Hamy A, Simonin M, Andrieu G, Queri M, et al.
Blood
. 2025 Feb;
PMID: 39977715
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre-TCR pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However,...
3.
Zeckanovic A, Mouttet B, Vinti L, Ancliff P, Brethon B, Cario G, et al.
Haematologica
. 2025 Feb;
PMID: 39911115
Not available.
4.
Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, et al.
Nat Med
. 2025 Jan;
PMID: 39779930
The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database,...
5.
Simonin M, Lainey E, Rialland F, Caye-Eude A, Reguerre Y, Boutroux H, et al.
Bull Cancer
. 2024 Nov;
PMID: 39492072
Acute leukemias of ambiguous lineage (ALAL) represent between 3 and 5% of childhood AL. This term encompasses many subtypes of AL that have been defined according to the immunophenotypic profile...
6.
Cousson S, Calvo C, Goldwirt L, Simonin M, Roupret-Serzec J, Dourthe M, et al.
Br J Haematol
. 2024 Oct;
206(1):209-214.
PMID: 39449171
BCL-2 inhibitor venetoclax demonstrates promising efficacy in paediatric relapsed/refractory acute myeloid leukaemia (r/r AML). This retrospective analysis evaluated 12 patients treated with venetoclax-based regimens under compassionate use for r/r myeloid...
7.
Strullu M, Caye-Eude A, Robert E, Renard J, Chaye A, Galimand J, et al.
Leukemia
. 2024 Oct;
39(1):64-74.
PMID: 39420220
Genetic alterations are the cornerstone of risk stratification in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and their accurate identification is critical for optimal treatment. Most cases with ABL-class fusion are...
8.
Bhatla T, Hogan L, Teachey D, Bautista F, Moppett J, Velasco Puyo P, et al.
Blood
. 2024 Aug;
144(21):2237-2247.
PMID: 39158071
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg...
9.
Ghobadi A, Aldoss I, Maude S, Bhojwani D, Wayne A, Bajel A, et al.
Res Sq
. 2024 Aug;
PMID: 39149468
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T cell product generated from healthy donor T...
10.
Lecornec N, Fahd M, De Lorenzo P, Valsecchi M, Micalizzi C, Diaz P, et al.
Br J Haematol
. 2024 Jul;
205(3):1230-1233.
PMID: 38982637
No abstract available.